Dasiglucagon

Introduction Overview

Generic Name

dasiglucagon

Brand Name

Zegalogue

Dosage Form

injection, for subcutaneous use

Drug Class

Glucose elevating agents

Pharmacokinetics

Absorption:
Dasiglucagon is administered via subcutaneous injection, enabling rapid absorption into the systemic circulation. Clinical pharmacokinetic studies demonstrate that dasiglucagon reaches peak plasma concentration (Cmax) typically within 30 minutes post subcutaneous administration. The bioavailability of dasiglucagon following subcutaneous injection is high, permitting effective therapeutic plasma levels essential for prompt reversal of severe hypoglycemia. The absorption rate can be influenced by local blood flow at the injection site and patient-specific factors such as skin temperature and injection technique.

Distribution:
Once absorbed, dasiglucagon distributes extensively throughout the extracellular fluid compartment. Plasma protein binding of dasiglucagon is limited, facilitating its availability to glucagon receptors in target tissues, primarily hepatocytes. Volume of distribution (Vd) approximates extracellular fluid volume, consistent with its peptide nature and hydrophilic properties. Dasiglucagon does not readily cross the blood-brain barrier, indicating its primary peripheral site of action.

Metabolism:
Dasiglucagon undergoes enzymatic degradation primarily by proteolytic enzymes in plasma and liver tissues. It is metabolized through cleavage of peptide bonds yielding smaller inactive fragments and amino acids, which are recycled or eliminated. Unlike native glucagon, dasiglucagon is a structurally modified glucagon analog designed to have increased stability and prolonged half-life, thus resisting rapid degradation by dipeptidyl peptidase IV and other proteases. This structural modification results in a longer duration of action.

Elimination:
Dasiglucagon and its metabolites are primarily eliminated via renal excretion of peptide fragments and amino acids. The elimination half-life ranges approximately between 0.5 to 1 hour, which allows for a sustained glucose-elevating effect sufficient for the treatment of severe hypoglycemia. Renal impairment may affect clearance, warranting clinical monitoring in affected populations. Due to its peptide nature, dasiglucagon is not significantly removed by hepatic metabolism or cytochrome P450 enzymes, limiting drug-drug interactions related to hepatic pathways.

Dosage Forms

Available Dosage Forms:
Zegalogue is available as a single-dose, prefilled injection for subcutaneous administration. It is provided in two delivery systems:
- Prefilled autoinjector containing dasiglucagon hydrochloride as a ready-to-use injectable solution.
- Prefilled syringe with dasiglucagon hydrochloride solution.
Both devices contain a single fixed dose of dasiglucagon designed for immediate use during severe hypoglycemic events.

Dosages for Adults and Adolescents:
The recommended dose of Zegalogue is a single fixed dose delivered via subcutaneous injection. The dose is uniform regardless of age or body weight in patients aged 6 years and older:
- 0.6 mg dasiglucagon per injection.
The fixed dosing facilitates ease of use during emergencies without need for dose calculations.

Specific Patient Populations:
- Pediatric Patients: Approved for use in children aged 6 years and older. Safety and efficacy have not been established in children younger than 6 years.
- Geriatric Patients: No specific dosage adjustments indicated; however, clinical judgment is advised based on individual patient status.
- Renal/Hepatic Impairment: No formal dose adjustments currently established, but caution advised due to potential altered metabolism and elimination.

Clinical Guidelines:
Zegalogue is indicated for the treatment of severe hypoglycemia requiring assistance from others. Caregivers should be trained on proper injection technique and emergency management protocols. If the patient does not respond within 15 minutes of initial dosing, a second dose may be administered if available.

Mechanism Of Action

Dasiglucagon is a novel glucagon analog with a mechanism of action centered on the activation of the glucagon receptor, a G protein-coupled receptor primarily expressed on hepatocytes. Upon subcutaneous administration, dasiglucagon binds to and activates these receptors, initiating intracellular signaling cascades via Gs protein-mediated activation of adenylate cyclase, which increases cyclic AMP (cAMP) levels.

Subsequent elevation of cAMP activates protein kinase A (PKA), which phosphorylates downstream targets leading to glycogenolysis, the breakdown of glycogen to glucose within the liver. This process rapidly increases the release of glucose into the bloodstream, effectively reversing hypoglycemia. Additionally, dasiglucagon stimulates gluconeogenesis, supporting sustained glucose production.

Dasiglucagon's structural modifications confer increased stability against enzymatic degradation compared to native glucagon. This prolongs its plasma half-life and maintains receptor activation over an extended period, enhancing its efficacy as a glucose-elevating agent, particularly in severe hypoglycemic emergencies.

Clinically, dasiglucagon's rapid and sustained action provides an important therapeutic advantage for treating patients with diabetes prone to severe hypoglycemia, facilitating prompt recovery with ease of administration through prefilled autoinjectors or syringes. Research studies have demonstrated that dasiglucagon achieves comparable or superior glycemic responses relative to endogenous glucagon preparations, with favorable safety and tolerability profiles.

Pharmacological Actions

Binds and activates hepatic glucagon receptors to stimulate glycogenolysis.
Increases intracellular cAMP leading to activation of protein kinase A.
Promotes hepatic glucose production through glycogen breakdown and gluconeogenesis.
Elevates blood glucose levels rapidly to counteract severe hypoglycemia.
Resists enzymatic degradation, resulting in a prolonged duration of action.
Induces metabolic effects similar to endogenous glucagon but with enhanced stability.
Facilitates rapid reversal of hypoglycemic symptoms requiring external assistance.
Administered via subcutaneous injection for ease in emergency settings.
Minimal cross-reactivity with other peptide receptors, providing specificity.
Does not interfere significantly with insulin secretion directly.
Activates lipolysis in adipose tissue as a secondary effect to increase glucose availability.
Minimal CNS penetration, focusing action on peripheral glucose metabolism.
Provides therapeutic benefits in individuals with diabetes mellitus experiencing insulin-induced hypoglycemia.
Does not require dose adjustment based on body weight or age (above 6 years).
Exhibits a tolerability profile consistent with glucagon receptor agonists.

Therapeutic Or Clinical Uses

Treatment of severe hypoglycemia in patients with diabetes mellitus aged 6 years and older.
Emergency use for hypoglycemic episodes requiring assistance due to impaired consciousness or inability to ingest carbohydrates orally.
Glucose elevating agent indicated for rapid reversal of insulin-induced hypoglycemia.
Alternative to traditional glucagon formulations with easier administration via autoinjector or prefilled syringe.
Use in outpatient and inpatient settings as part of hypoglycemia management protocols.
Potentially useful in pediatric populations aged 6 years and above experiencing severe hypoglycemia.
Prescribed to patients at high risk of severe hypoglycemic events, including type 1 and insulin-treated type 2 diabetes.
Supports caregivers’ ability to provide timely treatment during hypoglycemic emergencies.
Facilitates prevention of hypoglycemia-related complications such as seizures and coma.
May be utilized in diabetes education programs emphasizing emergency preparedness.
Designed to enhance safety and ease of use compared to reconstitution-required glucagon kits.
Can serve as part of hospital emergency kits for managing acute hypoglycemia.
Advised for patients with a history of severe hypoglycemic episodes unresponsive to oral glucose.
Has shown clinical efficacy in trials with robust glycemic recovery following dosing.
Not indicated for treatment of hyperinsulinemic hypoglycemia due to insulinoma or other tumorous conditions.

Side Or Adverse Effects

Nausea, a common side effect post administration.
Vomiting occurring in some patients following injection.
Headache reported as a frequent adverse reaction.
Diarrhea observed in adult patients during clinical use.
Injection site pain including erythema, swelling, or discomfort.
Potential for high blood pressure in patients with pheochromocytoma.
Risk of low blood sugar in patients with insulinoma following administration.
Serious allergic reactions including rash, hypotension, and respiratory difficulty are possible.
Injection site hypersensitivity or localized allergic response.
Dizziness or lightheadedness, possibly secondary to glucose fluctuations.
Transient tachycardia or palpitations due to glucagon’s metabolic effects.
Rare risk of hypoglycemia recurrence following initial treatment.
Potential for unintentional needle stick injury if not handled properly.
Latex allergy reactions due to natural rubber in needle coverings in sensitive individuals.
Gastrointestinal discomfort such as abdominal pain or bloating.

Precautions

Do not use in patients with pheochromocytoma due to risk of hypertensive crisis.
Contraindicated in patients with insulinoma due to risk of paradoxical hypoglycemia.
Ensure caregivers are trained thoroughly on proper injection technique before use.
Avoid use if patient has known allergy to dasiglucagon or formulation excipients.
Monitor blood pressure in patients with adrenal gland disorders during use.
Use caution in patients with prolonged fasting or malnutrition.
Inform healthcare providers of all current medications to anticipate interactions.
Pregnancy and breastfeeding safety have not been firmly established; consult healthcare provider.
Store properly to maintain efficacy; avoid freezing and adhere to expiration dates.
Educate patients and caregivers on signs of recurring hypoglycemia after treatment.
Do not expose to excessive heat or direct sunlight which can degrade the drug.
Ensure autoinjector or syringe is not damaged prior to administration.
Carry updated emergency contact information post-administration to facilitate urgent care.
Dispose of sharps safely in appropriate containers to prevent injury or contamination.
Avoid injecting through clothing; ensure the injection site is bare skin to guarantee absorption.

Warnings

Risk of severe allergic reactions including anaphylaxis; seek immediate medical attention if symptoms occur.
Hypertensive crises may occur in patients with adrenal tumors; discontinue use in these cases.
Hypoglycemia may recur after initial treatment; continuous monitoring is critical.
Do not delay emergency medical assistance after administration, even if symptoms improve.
Caregivers should be prepared to administer a second dose if no response in 15 minutes.
Do not reuse the prefilled autoinjector or syringe; it contains a single dose only.
Improper injection technique can result in inadequate dosing or injury.
Storage outside recommended temperature ranges may reduce effectiveness and safety.
Latex components in the device may cause allergic reactions in sensitive patients.
Use with caution in individuals with cardiovascular disease due to possible metabolic stress.
Not intended for self-administration in unconscious patients; caregiver involvement is necessary.
Potential drug interactions may alter therapeutic efficacy or increase adverse effects.
Avoid using expired product as potency and safety cannot be guaranteed.
Overdose or repeated dosing without medical supervision can lead to severe complications.
Discontinue use and report any unusual symptoms or reactions immediately to healthcare provider.

Contraindication

Presence of pheochromocytoma, an adrenal gland tumor.
Insulinoma, a tumor of the pancreatic beta cells.
Known allergy or hypersensitivity to dasiglucagon or any excipients in the formulation.
Do not use if the autoinjector or syringe is missing the gray cap or appears damaged.
Expired medication beyond the labeled expiration date.
Patients under 6 years of age due to lack of safety and efficacy data.
Use in individuals with prolonged fasting without medical supervision.
Patients with known latex allergy should use caution due to natural rubber in needle coverings.
Any condition where rapid glucose elevation is contraindicated or requires alternative management.
Not to be used as a routine treatment for mild or moderate hypoglycemia manageable with oral carbohydrates.
Contraindicated for use in hypoglycemia caused by non-insulin related disorders without medical advice.
Use contraindicated if there is inability or unwillingness of caregiver to perform injection properly.
Avoid use in patients with severe renal or hepatic impairment without clinician guidance.
Not recommended for repeated use without reevaluation by healthcare professional.

Drug Interactions

Indomethacin may inhibit dasiglucagon’s hyperglycemic effects, potentially reducing efficacy.
Warfarin’s anticoagulant effect may be potentiated by dasiglucagon, increasing bleeding risk.
Concurrent use with beta-blockers may mask some hypoglycemia symptoms while not affecting dasiglucagon action.
Drugs affecting hepatic glucose metabolism may alter dasiglucagon's effectiveness.
Co-administration with insulin can affect blood glucose trends; dose adjustments may be necessary.
Interactions with corticosteroids may influence glucose homeostasis and counter-regulatory responses.
Use with other glucose-elevating agents should be monitored to prevent hyperglycemia.
Monitoring is recommended with concomitant use of medications influencing gastrointestinal motility.
Herbal supplements impacting blood sugar (e.g., ginseng, bitter melon) may affect dasiglucagon’s therapeutic response.
Certain antibiotics may affect glucagon receptor function indirectly, though clinical significance is unclear.
Vitamin supplements, especially vitamin B complex, have no known significant interactions but should be disclosed.
Caution advised with drugs metabolized hepatically though dasiglucagon itself does not induce or inhibit cytochrome P450 enzymes.
Clinical monitoring advised when polypharmacy complicates glycemic management.
Nonsteroidal anti-inflammatory drugs (NSAIDs) like indomethacin can reduce glucose elevation induced by dasiglucagon.
Potential interactions with oral anticoagulants necessitate close coagulation monitoring.

Preparations Of The Drug

Active ingredient: dasiglucagon provided as dasiglucagon hydrochloride.
Formulated as a sterile, preservative-free aqueous solution for injection.
Inactive ingredients include tromethamine, sodium chloride, and water for injection.
pH adjusted with hydrochloric acid and/or sodium hydroxide to maintain stability.
Available in single-dose prefilled autoinjectors containing 0.6 mg dasiglucagon per device.
Also provided as single-dose prefilled syringes with 0.6 mg dasiglucagon dose.
Red protective case included to store and protect the injection device.
Devices consist of natural rubber components that may induce latex allergy in sensitive patients.
Instructions for use include detailed steps for autoinjector and syringe administration.
Supplied in temperature-controlled packaging to maintain drug stability during distribution.
Shelf life approximately 18 months with storage recommendations at 2°C to 8°C refrigeration.
Can be stored at room temperature (20°C to 25°C) for up to 12 months post removal from refrigeration.
Single-use devices are disposable following FDA guidelines for sharps disposal.
Each unit is individually packaged with instructional materials and safety labeling.
Free from preservatives, minimizing risk of adverse reactions related to additives.